WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Anticonvulsant Efficacy Endpoints - v1, Patients suffer from Infantile spasms (IS), Subtypes include Partial secondarily generalized seizures, Partial onset seizures are treated using Potiga, Sabril (Vigabatrin) treats Infantile spasms (IS), Complex partial seizures (CPS) are classified as Type 1B, Serious adverse events (SAEs) include Bronchospasm, Last spasm date is reported by Caregiver, Closed Circuit Television Electroencephalography (CCTV-EEG) monitoring is recorded for Defined timepoints (5), Intramyelinic edema (IME) is diagnosed by Histopathology, Secondary Endpoints include Psychomotor development, Serious adverse events (SAEs) include Convulsion, Potiga is also known as Ezogabine, % change in total partial seizure frequency is assessed between Baseline, Partial secondarily generalized seizures are classified as Type 1C, Patients can experience Motor function abnormalities, Visual toxicity is assessed by Ophthamologists, Subtypes include Complex partial seizures (CPS), Defined timepoints include 3 months, Potiga can be dosed at 1200 mg/day, MRI signal abnormalities can occur Transiently